Core Insights - Several biotechnology and pharmaceutical stocks experienced significant price increases during after-hours trading, driven by upcoming data releases, recent earnings reports, and prior corporate updates [1] Company Summaries - InflaRx N.V. (IFRX) saw a surge of 63.41% to $2.01 after hours, following a 2.50% gain at the close, due to plans to release topline data from its Phase 2a trial of oral C5aR inhibitor INF904, expected on Monday morning alongside its third-quarter financial results [2] - Rallybio Corp. (RLYB) rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, or $0.36 per share, reversing a prior-year loss of $11.5 million, although revenue for the quarter was $0.2 million, slightly below the $0.3 million reported in the same period last year [3] - FibroBiologics Inc. (FBLG) climbed 13.51% to $0.40 after hours, building on a 5.13% gain during regular trading, following the release of its third-quarter financial results and a corporate update on October 31 [4] - AbCellera Biologics Inc. (ABCL) advanced 6.51% to $4.16 after hours, recovering from a 13.69% decline earlier in the day, reporting a third-quarter net loss of $57.1 million, or $(0.19) per share, compared to a loss of $51.1 million in the same quarter last year, while revenue increased to $9.0 million from $6.5 million year-over-year [5] - BioRestorative Therapies Inc. (BRTX) gained 11.68% to $1.53 in after-hours trading, following a Notice of Allowance from the Japanese Patent Office for its ThermoStem platform announced on October 27, with third-quarter results scheduled for release on November 12 [6] - Cellectis S.A. (CLLS) rose 6.58% to $3.40 after hours, reporting a third-quarter net income of $589 thousand, or $0.01 per share, compared to a $23.1 million loss in the prior year, with total revenues and other income more than doubling to $37.2 million from $18.1 million [7]